Capricor Therapeutics Inc banner

Company Overview

Business Description

Sector
Health Care
Industry
Biotechnology
Headquarters
United States of America US
Employees
231
IPO date
Jun 4, 2002

Capricor Therapeutics is a biotechnology company that develops cell-based medicines for serious diseases, with a main focus on heart and muscle disorders. Its lead program is deramiocel, an allogeneic cardiosphere-derived cell therapy being studied for Duchenne muscular dystrophy, a genetic disease that weakens muscles over time. The company also works on exosome-based therapies, which use tiny particles released by cells as a way to deliver treatment signals.

The company does not sell a broad range of drugs. It earns money mainly through research and development funding, collaboration payments, and, if its programs succeed, potential future product sales or licensing deals. Its main customers are not typical consumers; they are regulators, research partners, doctors, hospitals, and eventually patients and payers if a therapy reaches the market.

What makes Capricor different is that it sits very early in the drug-development chain and focuses on hard-to-treat rare diseases where standard medicines often do not help enough. Instead of making mass-market pills, it is building specialized biologic treatments that must be tested, approved, and then delivered through clinical and medical channels.

Capricor Therapeutics Inc Investor Relations

Address
10865 Road to the Cure, Suite 150
San Diego, California
United States of America

Business Segments

Cell therapy

Capricor develops cell-based medicines for Duchenne muscular dystrophy and other serious muscle and heart conditions. Its work centers on engineered cells and related biologic treatments that are tested in clinical trial...

Customers and revenue model

Exosome therapy

Capricor also develops exosome-based treatments, which use tiny particles from cells to deliver therapeutic material to the body. This part of the business supports research programs and future drug candidates.

Customers and revenue model

Management

Dr. Frank Isaac Litvack FACC, M.D.

Executive Chairman of the Board

Biography unavailable

Dr. Linda Marbán Ph.D.

Co-Founder, President, CEO & Director

Biography unavailable

Mr. Anthony J. Bergmann M.B.A.

CFO & Corporate Treasurer

Biography unavailable

Ms. Karen G. Krasney

Executive VP, General Counsel & Secretary

Biography unavailable

Dr. Kristi A. H. Elliott Ph.D.

Chief Science Officer

Biography unavailable

Catherine Lee Kelleher

Consultant

Biography unavailable

1 / 6